CareDx sees Q3 revenue $82M-$83M, consensus $79.53M

Third quarter revenue is expected to be in the range of $82 million to $83 million, an increase of approximately 23% year-over-year. Grew Testing Services volume to approximately 44,600, an increase of approximately 16% year-over-year. Testing services revenue is expected to be in the range of $60 million to $61 million, an increase of approximately 26% year-over-year. This includes approximately $1.2 million in revenue for tests performed in prior quarters. Patient and Digital Solutions revenue is expected to be approximately $11.9 million, and Products is expected to be approximately $10.2 million, up 20% and 7% year-over-year, respectively. Ended the quarter with cash, cash equivalents, and marketable securities of approximately $240 million with no debt. “We are pleased to report another quarter of growth across all our lines of business. Our performance continues to be strong as we head into the fourth quarter,” said John Hanna, CareDx President and CEO.